WIESBADEN, Germany, May 14, 2013 /PRNewswire/ -- OrbusNeich Medical Inc. and its subsidiary, OrbusNeich Medical GmbH (collectively, "OrbusNeich"), today announced that the Dusseldorf Regional Court has issued a second preliminary injunction against the importation, distribution, sales and marketing of certain stent systems by Boston Scientific in Germany. This preliminary injunction was issued ex-parte against two companies – Boston Scientific (UK) Ltd. and Boston Scientific Ltd. – that Boston Scientific was using to intentionally circumvent a prior order of the Court banning sales of the same stent systems in Germany by other entities in the Boston Scientific corporate group.
On April 30, 2013, the Regional Court issued a preliminary injunction against U.S.-based Boston Scientific Corporation (NYSE: BSX) and its German subsidiary Boston Scientific Medizintechnik GmbH, prohibiting the importation, distribution, sales and marketing in Germany of the Small Vessel, Small Workhorse and Workhorse Stents of Boston Scientific's PROMUS Element ™ , PROMUS Element Plus ™ , OMEGA ™ , TAXUS Element ™ , SYNERGY ™ and Promus PREMIER ™ product lines. In its April 30 decision, which Boston Scientific has appealed, the Regional Court found that the geometric pattern of these stents infringe OrbusNeich's patent EP 1 341 482. As previously announced, OrbusNeich enforced the injunction on May 7, 2013. From that date forward, Boston Scientific Corporation and its German subsidiary were prohibited from taking any further actions that would infringe the '482 patent in Germany.
Rather than respecting the injunction, Boston Scientific immediately took steps to circumvent it. Boston Scientific transferred the German distribution of these products to Boston Scientific (UK) Ltd. and Boston Scientific Ltd. The company then sent a letter to its German customers advising them of the injunction and announcing that infringing products could be ordered from Boston Scientific UK. The letter provided contact information for orders and assured customers that a German-speaking salesperson would be at their disposal. These acts prompted the filing of the second preliminary injunction request, which was granted yesterday and which Boston Scientific may appeal. OrbusNeich has immediately initiated enforcement of this new preliminary injunction.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV